-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
1642588228
-
Pancreatic cancer
-
DOI 10.1016/S0140-6736(04)15841-8, PII S0140673604158418
-
Li D, Xie K, Wolff R, Abbruzzese JL,. Pancreatic cancer. Lancet 2004; 363: 1049-57. (Pubitemid 38410779)
-
(2004)
Lancet
, vol.363
, Issue.9414
, pp. 1049-1057
-
-
Li, D.1
Xie, K.2
Wolff, R.3
Abbruzzese, J.L.4
-
3
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13. (Pubitemid 27251144)
-
(1997)
Journal of Clinical Oncology
, vol.15
, Issue.6
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
Cripps, M.C.7
Portenoy, R.K.8
Storniolo, A.M.9
Tarassoff, P.10
Nelson, R.11
Dorr, F.A.12
Stephens, C.D.13
Von Hoff, D.D.14
-
4
-
-
67349117952
-
Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy
-
Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M,. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009; 35: 335-9.
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 335-339
-
-
Rivera, F.1
Lopez-Tarruella, S.2
Vega-Villegas, M.E.3
Salcedo, M.4
-
5
-
-
73949135518
-
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
-
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-18.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5513-5518
-
-
Cunningham, D.1
Chau, I.2
Stocken, D.D.3
Valle, J.W.4
Smith, D.5
Steward, W.6
Harper, P.G.7
Dunn, J.8
Tudur-Smith, C.9
West, J.10
Falk, S.11
Crellin, A.12
-
6
-
-
19944409357
-
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial
-
DOI 10.1016/S1470-2045(05)70175-3, PII S1470204505701753
-
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-76. (Pubitemid 40753742)
-
(2005)
Lancet Oncology
, vol.6
, Issue.6
, pp. 369-376
-
-
Reni, M.1
Cordio, S.2
Milandri, C.3
Passoni, P.4
Bonetto, E.5
Oliani, C.6
Luppi, G.7
Nicoletti, R.8
Galli, L.9
Bordonaro, R.10
Passardi, A.11
Zerbi, A.12
Balzano, G.13
Aldrighetti, L.14
Staudacher, C.15
Villa, E.16
Di Carlo, V.17
-
7
-
-
60149088848
-
Origins and mechanisms of miRNAs and siRNAs
-
Carthew RW, Sontheimer EJ,. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
-
(2009)
Cell
, vol.136
, pp. 642-655
-
-
Carthew, R.W.1
Sontheimer, E.J.2
-
8
-
-
20444460289
-
MicroRNA expression profiles classify human cancers
-
DOI 10.1038/nature03702
-
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8. (Pubitemid 40839735)
-
(2005)
Nature
, vol.435
, Issue.7043
, pp. 834-838
-
-
Lu, J.1
Getz, G.2
Miska, E.A.3
Alvarez-Saavedra, E.4
Lamb, J.5
Peck, D.6
Sweet-Cordero, A.7
Ebert, B.L.8
Mak, R.H.9
Ferrando, A.A.10
Downing, J.R.11
Jacks, T.12
Horvitz, H.R.13
Golub, T.R.14
-
9
-
-
12144290519
-
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
-
DOI 10.1073/pnas.0307323101
-
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM,. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004. (Pubitemid 38327724)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.9
, pp. 2999-3004
-
-
Calin, G.A.1
Sevignani, C.2
Dumitru, C.D.3
Hyslop, T.4
Noch, E.5
Yendamuri, S.6
Shimizu, M.7
Rattan, S.8
Bullrich, F.9
Negrini, M.10
Croce, C.M.11
-
10
-
-
23644434724
-
Overexpression of neuropilin-1 promotes constitutive MARK signalling and chemoresistance in pancreatic cancer cells
-
DOI 10.1038/sj.bjc.6602663
-
Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM,. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 2005; 93: 233-41. (Pubitemid 41133210)
-
(2005)
British Journal of Cancer
, vol.93
, Issue.2
, pp. 233-241
-
-
Wey, J.S.1
Gray, M.J.2
Fan, F.3
Belcheva, A.4
McCarty, M.F.5
Stoeltzing, O.6
Somcio, R.7
Liu, W.8
Evans, D.B.9
Klagsbrun, M.10
Gallick, G.E.11
Ellis, L.M.12
-
11
-
-
0036057585
-
Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes
-
DOI 10.1159/000065068
-
Shi X, Liu S, Kleeff J, Friess H, Buchler MW,. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-62. (Pubitemid 34914105)
-
(2002)
Oncology
, vol.62
, Issue.4
, pp. 354-362
-
-
Shi, X.1
Liu, S.2
Kleeff, J.3
Friess, H.4
Buchler, M.W.5
-
12
-
-
34547120221
-
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer
-
DOI 10.1158/0008-5472.CAN-07-0440
-
Mahon PC, Baril P, Bhakta V, Chelala C, Caulee K, Harada T, Lemoine NR,. S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res 2007; 67: 6786-95. (Pubitemid 47105526)
-
(2007)
Cancer Research
, vol.67
, Issue.14
, pp. 6786-6795
-
-
Mahon, P.C.1
Baril, P.2
Bhakta, V.3
Chelala, C.4
Caulee, K.5
Harada, T.6
Lemoine, N.R.7
-
13
-
-
0038621384
-
Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
-
DOI 10.1038/sj.onc.1206390
-
Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR, Schafer H,. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51. (Pubitemid 36712936)
-
(2003)
Oncogene
, vol.22
, Issue.21
, pp. 3243-3251
-
-
Arlt, A.1
Gehrz, A.2
Muerkoster, S.3
Vorndamm, J.4
Kruse, M.-L.5
Folsch, U.R.6
Schafer, H.7
-
14
-
-
74549213069
-
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines
-
Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L,. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer 2009; 8: 125.
-
(2009)
Mol Cancer
, vol.8
, pp. 125
-
-
Huanwen, W.1
Zhiyong, L.2
Xiaohua, S.3
Xinyu, R.4
Kai, W.5
Tonghua, L.6
-
15
-
-
0842329842
-
CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells
-
DOI 10.1038/sj.onc.1207036
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004; 23: 465-73. (Pubitemid 38175001)
-
(2004)
Oncogene
, vol.23
, Issue.2
, pp. 465-473
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
16
-
-
60749122433
-
Alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma
-
Sebens Muerkoster S, Kotteritzsch J, Geismann C, Gast D, Kruse ML, Altevogt P, Folsch UR, Schafer H,. alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int J Oncol 2009; 34: 243-53.
-
(2009)
Int J Oncol
, vol.34
, pp. 243-253
-
-
Sebens Muerkoster, S.1
Kotteritzsch, J.2
Geismann, C.3
Gast, D.4
Kruse, M.L.5
Altevogt, P.6
Folsch, U.R.7
Schafer, H.8
-
17
-
-
40949087142
-
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma
-
DOI 10.1158/1078-0432.CCR-07-1450
-
Liau SS, Whang E,. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008; 14: 1470-7. (Pubitemid 351413931)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.5
, pp. 1470-1477
-
-
Liau, S.-S.1
Whang, E.E.2
-
18
-
-
18244381555
-
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance
-
DOI 10.1158/1078-0432.CCR-04-1510
-
Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE,. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res 2005; 11: 3433-8. (Pubitemid 40627897)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.9
, pp. 3433-3438
-
-
Duxbury, M.S.1
Ito, H.2
Benoit, E.3
Waseem, T.4
Ashley, S.W.5
Whang, E.E.6
-
19
-
-
36349006961
-
Development and characterization of gemcitabine-resistant pancreatic tumor cells
-
DOI 10.1245/s10434-007-9583-5
-
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE,. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007; 14: 3629-37. (Pubitemid 350160137)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.12
, pp. 3629-3637
-
-
Shah, A.N.1
Summy, J.M.2
Zhang, J.3
Park, S.I.4
Parikh, N.U.5
Gallick, G.E.6
-
20
-
-
65549141305
-
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway
-
Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH,. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-7.
-
(2009)
Cancer Res
, vol.69
, pp. 2400-2407
-
-
Wang, Z.1
Li, Y.2
Kong, D.3
Banerjee, S.4
Ahmad, A.5
Azmi, A.S.6
Ali, S.7
Abbruzzese, J.L.8
Gallick, G.E.9
Sarkar, F.H.10
-
21
-
-
67650999217
-
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer
-
Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W,. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69: 5820-8.
-
(2009)
Cancer Res
, vol.69
, pp. 5820-5828
-
-
Arumugam, T.1
Ramachandran, V.2
Fournier, K.F.3
Wang, H.4
Marquis, L.5
Abbruzzese, J.L.6
Gallick, G.E.7
Logsdon, C.D.8
McConkey, D.J.9
Choi, W.10
-
22
-
-
33846958737
-
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer
-
Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 2007; 120: 1355-63.
-
(2007)
Int J Cancer
, vol.120
, pp. 1355-1363
-
-
Nakahira, S.1
Nakamori, S.2
Tsujie, M.3
Takahashi, Y.4
Okami, J.5
Yoshioka, S.6
Yamasaki, M.7
Marubashi, S.8
Takemasa, I.9
Miyamoto, A.10
Takeda, Y.11
Nagano, H.12
-
23
-
-
77951705674
-
Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: Increased expression of interferon-stimulated gene 15 kD is associated with intrinsic chemoresistance
-
Ina S, Hirono S, Noda T, Yamaue H,. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kD is associated with intrinsic chemoresistance. Pancreas 2010; 39: 473-85.
-
(2010)
Pancreas
, vol.39
, pp. 473-485
-
-
Ina, S.1
Hirono, S.2
Noda, T.3
Yamaue, H.4
-
24
-
-
1542742114
-
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine
-
DOI 10.1038/sj.onc.1207272
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23: 1539-48. (Pubitemid 38406516)
-
(2004)
Oncogene
, vol.23
, Issue.8
, pp. 1539-1548
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
25
-
-
1642551021
-
Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells
-
DOI 10.1158/1078-0432.CCR-1183-3
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004; 10: 2307-18. (Pubitemid 38445688)
-
(2004)
Clinical Cancer Research
, vol.10
, Issue.7
, pp. 2307-2318
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
26
-
-
50249152822
-
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer
-
Michalski CW, Erkan M, Sauliunaite D, Giese T, Stratmann R, Sartori C, Giese NA, Friess H, Kleeff J,. Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 2008; 99: 760-7.
-
(2008)
Br J Cancer
, vol.99
, pp. 760-767
-
-
Michalski, C.W.1
Erkan, M.2
Sauliunaite, D.3
Giese, T.4
Stratmann, R.5
Sartori, C.6
Giese, N.A.7
Friess, H.8
Kleeff, J.9
-
27
-
-
25444493107
-
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer
-
DOI 10.1158/0008-5472.CAN-05-1330
-
Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao PJ, Philip PA, Abbruzzese J, Sarkar FH,. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res 2005; 65: 9064-72. (Pubitemid 41377399)
-
(2005)
Cancer Research
, vol.65
, Issue.19
, pp. 9064-9072
-
-
Banerjee, S.1
Zhang, Y.2
Ali, S.3
Bhuiyan, M.4
Wang, Z.5
Chiao, P.J.6
Philip, P.A.7
Abbruzzese, J.8
Sarkar, F.H.9
-
28
-
-
34248573808
-
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products
-
DOI 10.1158/0008-5472.CAN-06-4257
-
Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB,. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-61. (Pubitemid 46762173)
-
(2007)
Cancer Research
, vol.67
, Issue.8
, pp. 3853-3861
-
-
Kunnumakkara, A.B.1
Guha, S.2
Krishnan, S.3
Diagaradjane, P.4
Gelovani, J.5
Aggarwal, B.B.6
-
29
-
-
21744434389
-
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis
-
DOI 10.1038/sj.onc.1208642
-
Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Buchler MW, Giese NA, Friess H,. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005; 24: 4421-32. (Pubitemid 40961765)
-
(2005)
Oncogene
, vol.24
, Issue.27
, pp. 4421-4432
-
-
Erkan, M.1
Kleeff, J.2
Esposito, I.3
Giese, T.4
Ketterer, K.5
Buchler, M.W.6
Giese, N.A.7
Friess, H.8
-
30
-
-
17144390205
-
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer
-
DOI 10.1158/1078-0432.CCR-04-1785
-
Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S, Lemoine NR,. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005; 11: 3094-101. (Pubitemid 40525216)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.8
, pp. 3094-3101
-
-
Akada, M.1
Crnogorac-Jurcevic, T.2
Lattimore, S.3
Mahon, P.4
Lopes, R.5
Sunamura, M.6
Matsuno, S.7
Lemoine, N.R.8
-
31
-
-
38649085043
-
Telomerase transcriptional targeting of inducible bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer
-
DOI 10.1038/sj.mt.6300340, PII 6300340
-
Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A,. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 2008; 16: 252-60. (Pubitemid 351168033)
-
(2008)
Molecular Therapy
, vol.16
, Issue.2
, pp. 252-260
-
-
Wack, S.1
Rejiba, S.2
Parmentier, C.3
Aprahamian, M.4
Hajri, A.5
-
32
-
-
59149087882
-
Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells
-
Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H,. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009; 69: 1156-65.
-
(2009)
Cancer Res
, vol.69
, pp. 1156-1165
-
-
Murtaza, I.1
Saleem, M.2
Adhami, V.M.3
Hafeez, B.B.4
Mukhtar, H.5
-
33
-
-
67650496175
-
3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer
-
Banerjee S, Wang Z, Kong D, Sarkar FH,. 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009; 69: 5592-600.
-
(2009)
Cancer Res
, vol.69
, pp. 5592-5600
-
-
Banerjee, S.1
Wang, Z.2
Kong, D.3
Sarkar, F.H.4
-
34
-
-
0037457422
-
Usage of the NF-κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer
-
DOI 10.1002/ijc.10963
-
Muerkoster S, Arlt A, Witt M, Gehrz A, Haye S, March C, Grohmann F, Wegehenkel K, Kalthoff H, Folsch UR, Schafer H,. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003; 104: 469-76. (Pubitemid 36323918)
-
(2003)
International Journal of Cancer
, vol.104
, Issue.4
, pp. 469-476
-
-
Muerkoster, S.1
Arlt, A.2
Witt, M.3
Gehrz, A.4
Haye, S.5
March, C.6
Grohmann, F.7
Wegehenkel, K.8
Kalthoff, H.9
Folsch, U.R.10
Schafer, H.11
-
35
-
-
36349013117
-
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells
-
DOI 10.1245/s10434-007-9556-8
-
Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, Babcock TA, Espat NJ,. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 2007; 14: 3620-8. (Pubitemid 350160123)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.12
, pp. 3620-3628
-
-
Hering, J.1
Garrean, S.2
Dekoj, T.R.3
Razzak, A.4
Saied, A.5
Trevino, J.6
Babcock, T.A.7
Espat, N.J.8
-
36
-
-
33645731188
-
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
-
Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S, Orlandini C, Boggi U, Campani D, Del Chiaro M, Iannopollo M, Bevilacqua G, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006; 66: 3928-35.
-
(2006)
Cancer Res
, vol.66
, pp. 3928-3935
-
-
Giovannetti, E.1
Del Tacca, M.2
Mey, V.3
Funel, N.4
Nannizzi, S.5
Ricci, S.6
Orlandini, C.7
Boggi, U.8
Campani, D.9
Del Chiaro, M.10
Iannopollo, M.11
Bevilacqua, G.12
-
37
-
-
33846816556
-
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
-
DOI 10.1038/sj.bjc.6603559, PII 6603559
-
Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y,. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96: 457-63. (Pubitemid 46215217)
-
(2007)
British Journal of Cancer
, vol.96
, Issue.3
, pp. 457-463
-
-
Nakano, Y.1
Tanno, S.2
Koizumi, K.3
Nishikawa, T.4
Nakamura, K.5
Minoguchi, M.6
Izawa, T.7
Mizukami, Y.8
Okumura, T.9
Kohgo, Y.10
-
38
-
-
67650485895
-
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies
-
Rejiba S, Bigand C, Parmentier C, Hajri A,. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009; 11: 637-50.
-
(2009)
Neoplasia
, vol.11
, pp. 637-650
-
-
Rejiba, S.1
Bigand, C.2
Parmentier, C.3
Hajri, A.4
-
39
-
-
33846666657
-
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells
-
DOI 10.1158/0008-5472.CAN-06-3166
-
Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M,. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 2007; 67: 684-94. (Pubitemid 46192208)
-
(2007)
Cancer Research
, vol.67
, Issue.2
, pp. 684-694
-
-
Tabe, Y.1
Jin, L.2
Tsutsumi-Ishii, Y.3
Xu, Y.4
McQueen, T.5
Priebe, W.6
Mills, G.B.7
Ohsaka, A.8
Nagaoka, I.9
Andreeff, M.10
Konopleva, M.11
-
40
-
-
27544505676
-
Chromatin modifier enzymes, the histone code and cancer
-
DOI 10.1016/j.ejca.2005.08.010, PII S0959804905007100, Transcription Factors in Cancer
-
Santos-Rosa H, Caldas C,. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 2005; 41: 2381-402. (Pubitemid 41540617)
-
(2005)
European Journal of Cancer
, vol.41
, Issue.16
, pp. 2381-2402
-
-
Santos-Rosa, H.1
Caldas, C.2
-
41
-
-
0036830642
-
Role of histone H3 lysine 27 methylation in polycomb-group silencing
-
DOI 10.1126/science.1076997
-
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y,. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43. (Pubitemid 35247314)
-
(2002)
Science
, vol.298
, Issue.5595
, pp. 1039-1043
-
-
Cao, R.1
Wang, L.2
Wang, H.3
Xia, L.4
Erdjument-Bromage, H.5
Tempst, P.6
Jones, R.S.7
Zhang, Y.8
-
42
-
-
32844459336
-
The Polycomb group protein EZH2 directly controls DNA methylation
-
DOI 10.1038/nature04431, PII NATURE04431
-
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-4. (Pubitemid 43255707)
-
(2006)
Nature
, vol.439
, Issue.7078
, pp. 871-874
-
-
Vire, E.1
Brenner, C.2
Deplus, R.3
Blanchon, L.4
Fraga, M.5
Didelot, C.6
Morey, L.7
Van Eynde, A.8
Bernard, D.9
Vanderwinden, J.-M.10
Bollen, M.11
Esteller, M.12
Di Croce, L.13
De Launoit, Y.14
Fuks, F.15
-
43
-
-
0242539836
-
Cancer epigenetics
-
Momparler RL,. Cancer epigenetics. Oncogene 2003; 22: 6479-83. (Pubitemid 37372327)
-
(2003)
Oncogene
, vol.22
, Issue.43
, pp. 6479-6483
-
-
Momparler, R.L.1
-
44
-
-
51949094991
-
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases
-
Muerkoster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, Tsao MS, Folsch UR, Schafer H,. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma-epigenetic downregulation of caspases. Int J Cancer 2008; 123: 1751-60.
-
(2008)
Int J Cancer
, vol.123
, pp. 1751-1760
-
-
Muerkoster, S.S.1
Werbing, V.2
Koch, D.3
Sipos, B.4
Ammerpohl, O.5
Kalthoff, H.6
Tsao, M.S.7
Folsch, U.R.8
Schafer, H.9
-
45
-
-
58149214373
-
Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2
-
Ougolkov AV, Bilim VN, Billadeau DD,. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008; 14: 6790-6.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6790-6796
-
-
Ougolkov, A.V.1
Bilim, V.N.2
Billadeau, D.D.3
-
46
-
-
25844465921
-
Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine)
-
DOI 10.1053/j.seminoncol.2005.07.008, PII S0093775405002770, Cancer Epigenetics
-
Momparler RL,. Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine). Semin Oncol 2005; 32: 443-51. (Pubitemid 41396420)
-
(2005)
Seminars in Oncology
, vol.32
, Issue.5
, pp. 443-451
-
-
Momparler, R.L.1
-
47
-
-
34250810709
-
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells
-
DOI 10.1002/ijc.22558
-
Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP,. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121: 656-65. (Pubitemid 46986501)
-
(2007)
International Journal of Cancer
, vol.121
, Issue.3
, pp. 656-665
-
-
Kumagai, T.1
Wakimoto, N.2
Yin, D.3
Gery, S.4
Kawamata, N.5
Takai, N.6
Komatsu, N.7
Chumakov, A.8
Imai, Y.9
Koeffler, H.P.10
-
48
-
-
67349285731
-
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors
-
Frew AJ, Johnstone RW, Bolden JE,. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125-33.
-
(2009)
Cancer Lett
, vol.280
, pp. 125-133
-
-
Frew, A.J.1
Johnstone, R.W.2
Bolden, J.E.3
-
49
-
-
70349309923
-
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA
-
Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, Saur D, Schneider G,. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009; 58: 1399-409.
-
(2009)
Gut
, vol.58
, pp. 1399-1409
-
-
Fritsche, P.1
Seidler, B.2
Schuler, S.3
Schnieke, A.4
Gottlicher, M.5
Schmid, R.M.6
Saur, D.7
Schneider, G.8
-
50
-
-
78650723028
-
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer
-
Ouaissi M, Giger U, Sielezneff I, Pirro N, Sastre B, Ouaissi A,. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011; 2011: 315939.
-
(2011)
J Biomed Biotechnol
, vol.2011
, pp. 315939
-
-
Ouaissi, M.1
Giger, U.2
Sielezneff, I.3
Pirro, N.4
Sastre, B.5
Ouaissi, A.6
-
51
-
-
0038343499
-
MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing
-
DOI 10.1016/S0092-8674(03)00428-8
-
Ambros V,. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113: 673-6. (Pubitemid 36724931)
-
(2003)
Cell
, vol.113
, Issue.6
, pp. 673-676
-
-
Ambros, V.1
-
52
-
-
28044455435
-
microPrimer: The biogenesis and function of microRNA
-
DOI 10.1242/dev.02070
-
Du T, Zamore PD,. microPrimer: the biogenesis and function of microRNA. Development 2005; 132: 4645-52. (Pubitemid 41685275)
-
(2005)
Development
, vol.132
, Issue.21
, pp. 4645-4652
-
-
Du, T.1
Zamore, P.D.2
-
53
-
-
10744225153
-
Asymmetry in the assembly of the RNAi enzyme complex
-
DOI 10.1016/S0092-8674(03)00759-1
-
Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD,. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115: 199-208. (Pubitemid 37329583)
-
(2003)
Cell
, vol.115
, Issue.2
, pp. 199-208
-
-
Schwarz, D.S.1
Hutvagner, G.2
Du, T.3
Xu, Z.4
Aronin, N.5
Zamore, P.D.6
-
54
-
-
0037144546
-
A microRNA in a multiple-turnover RNAi enzyme complex
-
Hutvagner G, Zamore PD,. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002; 297: 2056-60.
-
(2002)
Science
, vol.297
, pp. 2056-2060
-
-
Hutvagner, G.1
Zamore, P.D.2
-
55
-
-
2442495329
-
RISC is a 5′ phosphomonoester-producing RNA endonuclease
-
Martinez J, Tuschl T,. RISC is a 5′ phosphomonoester-producing RNA endonuclease. Genes Dev 2004; 18: 975-80.
-
(2004)
Genes Dev
, vol.18
, pp. 975-980
-
-
Martinez, J.1
Tuschl, T.2
-
56
-
-
33749059160
-
MiRBase: The microRNA sequence database
-
Griffiths-Jones S,. miRBase: the microRNA sequence database. Methods Mol Biol 2006; 342: 129-38.
-
(2006)
Methods Mol Biol
, vol.342
, pp. 129-138
-
-
Griffiths-Jones, S.1
-
57
-
-
38549150275
-
miRBase: Tools for microRNA genomics
-
DOI 10.1093/nar/gkm952
-
Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ,. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36 (Database issue): D154-D158. (Pubitemid 351149713)
-
(2008)
Nucleic Acids Research
, vol.36
, Issue.SUPPL. 1
-
-
Griffiths-Jones, S.1
Saini, H.K.2
Van Dongen, S.3
Enright, A.J.4
-
58
-
-
34247540446
-
Epigenetics and microRNAs
-
DOI 10.1203/pdr.0b013e3180457684
-
Chuang JC, Jones PA,. Epigenetics and microRNAs. Pediatr Res 2007; 61 (Part 2): 24R-29R. (Pubitemid 46653064)
-
(2007)
Pediatric Research
, vol.61
, Issue.5 PART 2 SUPPL.
-
-
Chuang, J.C.1
Jones, P.A.2
-
59
-
-
38749089854
-
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
-
DOI 10.1001/jama.299.4.425
-
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36. (Pubitemid 351185951)
-
(2008)
JAMA - Journal of the American Medical Association
, vol.299
, Issue.4
, pp. 425-436
-
-
Schetter, A.J.1
Leung, S.Y.2
Sohn, J.J.3
Zanetti, K.A.4
Bowman, E.D.5
Yanaihara, N.6
Yuen, S.T.7
Chan, T.L.8
Kwong, D.L.W.9
Au, G.K.H.10
Liu, C.-G.11
Calin, G.A.12
Croce, C.M.13
Harris, C.C.14
-
60
-
-
55549120234
-
MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis
-
Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY,. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-60.
-
(2008)
RNA
, vol.14
, pp. 2348-2360
-
-
Yan, L.X.1
Huang, X.F.2
Shao, Q.3
Huang, M.Y.4
Deng, L.5
Wu, Q.L.6
Zeng, Y.X.7
Shao, J.Y.8
-
61
-
-
50849137458
-
MicroRNA expression profiles in serous ovarian carcinoma
-
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S,. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14: 2690-5.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2690-2695
-
-
Nam, E.J.1
Yoon, H.2
Kim, S.W.3
Kim, H.4
Kim, Y.T.5
Kim, J.H.6
Kim, J.W.7
Kim, S.8
-
62
-
-
67449164586
-
MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor
-
Li J, Huang H, Sun L, Yang M, Pan C, Chen W, Wu D, Lin Z, Zeng C, Yao Y, Zhang P, Song E,. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009; 15: 3998-4008.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3998-4008
-
-
Li, J.1
Huang, H.2
Sun, L.3
Yang, M.4
Pan, C.5
Chen, W.6
Wu, D.7
Lin, Z.8
Zeng, C.9
Yao, Y.10
Zhang, P.11
Song, E.12
-
63
-
-
39049086391
-
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN
-
DOI 10.1158/0008-5472.CAN-07-2488
-
Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ,. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-33. (Pubitemid 351380068)
-
(2008)
Cancer Research
, vol.68
, Issue.2
, pp. 425-433
-
-
Yang, H.1
Kong, W.2
He, L.3
Zhao, J.-J.4
O'Donnell, J.D.5
Wang, J.6
Wenham, R.M.7
Coppola, D.8
Kruk, P.A.9
Nicosia, S.V.10
Cheng, J.Q.11
-
64
-
-
34547524771
-
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
-
DOI 10.1053/j.gastro.2007.05.022, PII S0016508507010025
-
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T,. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58. (Pubitemid 47187346)
-
(2007)
Gastroenterology
, vol.133
, Issue.2
, pp. 647-658
-
-
Meng, F.1
Henson, R.2
Wehbe-Janek, H.3
Ghoshal, K.4
Jacob, S.T.5
Patel, T.6
-
65
-
-
77956165602
-
Analyzing miRNAs in ductal adenocarcinomas of the pancreas
-
Mees ST, Schleicher C, Mardin WA, Senninger N, Colombo-Benkmann M, Haier J,. Analyzing miRNAs in ductal adenocarcinomas of the pancreas. J Surg Res, 2009.
-
(2009)
J Surg Res
-
-
Mees, S.T.1
Schleicher, C.2
Mardin, W.A.3
Senninger, N.4
Colombo-Benkmann, M.5
Haier, J.6
-
66
-
-
70350425809
-
MicroRNAs: Novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
-
Mardin WA, Mees ST,. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol 2009; 16: 3183-9.
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 3183-3189
-
-
Mardin, W.A.1
Mees, S.T.2
-
67
-
-
73449085536
-
EP300-a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas
-
Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J,. EP300-a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 2010; 126: 114-24.
-
(2010)
Int J Cancer
, vol.126
, pp. 114-124
-
-
Mees, S.T.1
Mardin, W.A.2
Wendel, C.3
Baeumer, N.4
Willscher, E.5
Senninger, N.6
Schleicher, C.7
Colombo-Benkmann, M.8
Haier, J.9
-
68
-
-
67650999145
-
Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas
-
Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J,. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009; 16: 2339-50.
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 2339-2350
-
-
Mees, S.T.1
Mardin, W.A.2
Sielker, S.3
Willscher, E.4
Senninger, N.5
Schleicher, C.6
Colombo-Benkmann, M.7
Haier, J.8
-
69
-
-
79959688690
-
Role of tumor microenvironment on gene expression in pancreatic cancer tumor models
-
Mees ST, Mardin WA, Schleicher C, Colombo-Benkmann M, Senninger N, Haier J,. Role of tumor microenvironment on gene expression in pancreatic cancer tumor models. J Surg Res, 2010.
-
(2010)
J Surg Res
-
-
Mees, S.T.1
Mardin, W.A.2
Schleicher, C.3
Colombo-Benkmann, M.4
Senninger, N.5
Haier, J.6
-
70
-
-
33846813656
-
Expression profiling identifies microRNA signature in pancreatic cancer
-
DOI 10.1002/ijc.22394
-
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD,. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-54. (Pubitemid 46214304)
-
(2007)
International Journal of Cancer
, vol.120
, Issue.5
, pp. 1046-1054
-
-
Eun, J.L.1
Gusev, Y.2
Jiang, J.3
Nuovo, G.J.4
Lerner, M.R.5
Frankel, W.L.6
Morgan, D.L.7
Postier, R.G.8
Brackett, D.J.9
Schmittgen, T.D.10
-
71
-
-
34247862190
-
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis
-
DOI 10.1001/jama.297.17.1901
-
Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM,. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-8. (Pubitemid 46707844)
-
(2007)
Journal of the American Medical Association
, vol.297
, Issue.17
, pp. 1901-1908
-
-
Bloomston, M.1
Frankel, W.L.2
Petrocca, F.3
Volinia, S.4
Alder, H.5
Hagan, J.P.6
Liu, C.-G.7
Bhatt, D.8
Taccioli, C.9
Croce, C.M.10
-
72
-
-
62549154091
-
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia
-
Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM, Maitra A,. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009; 8: 340-6.
-
(2009)
Cancer Biol Ther
, vol.8
, pp. 340-346
-
-
Habbe, N.1
Koorstra, J.B.2
Mendell, J.T.3
Offerhaus, G.J.4
Ryu, J.K.5
Feldmann, G.6
Mullendore, M.E.7
Goggins, M.G.8
Hong, S.M.9
Maitra, A.10
-
73
-
-
70449700281
-
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease
-
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, Sen S,. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-13.
-
(2009)
Cancer Prev Res (Phila)
, vol.2
, pp. 807-813
-
-
Wang, J.1
Chen, J.2
Chang, P.3
Leblanc, A.4
Li, D.5
Abbruzzesse, J.L.6
Frazier, M.L.7
Killary, A.M.8
Sen, S.9
-
74
-
-
80051572484
-
Roles and mechanisms of MicroRNAs in pancreatic cancer
-
Zhang L, Jamaluddin MS, Weakley SM, Yao Q, Chen C,. Roles and mechanisms of MicroRNAs in pancreatic cancer. World J Surg, 2011.
-
(2011)
World J Surg
-
-
Zhang, L.1
Jamaluddin, M.S.2
Weakley, S.M.3
Yao, Q.4
Chen, C.5
-
75
-
-
78549293104
-
Dysregulation of miR-15a and miR-214 in human pancreatic cancer
-
Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ,. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010; 3: 46.
-
(2010)
J Hematol Oncol
, vol.3
, pp. 46
-
-
Zhang, X.J.1
Ye, H.2
Zeng, C.W.3
He, B.4
Zhang, H.5
Chen, Y.Q.6
-
76
-
-
77953169001
-
MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity
-
Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010; 70: 4528-38.
-
(2010)
Cancer Res
, vol.70
, pp. 4528-4538
-
-
Giovannetti, E.1
Funel, N.2
Peters, G.J.3
Del Chiaro, M.4
Erozenci, L.A.5
Vasile, E.6
Leon, L.G.7
Pollina, L.E.8
Groen, A.9
Falcone, A.10
Danesi, R.11
Campani, D.12
-
77
-
-
77956296766
-
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer
-
Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5: e10630.
-
(2010)
PLoS One
, vol.5
-
-
Hwang, J.H.1
Voortman, J.2
Giovannetti, E.3
Steinberg, S.M.4
Leon, L.G.5
Kim, Y.T.6
Funel, N.7
Park, J.K.8
Kim, M.A.9
Kang, G.H.10
Kim, S.W.11
Del Chiaro, M.12
-
78
-
-
70349904531
-
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma
-
Park JK, Lee EJ, Esau C, Schmittgen TD,. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009; 38: e190-e199.
-
(2009)
Pancreas
, vol.38
-
-
Park, J.K.1
Lee, E.J.2
Esau, C.3
Schmittgen, T.D.4
-
79
-
-
77951745289
-
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF
-
Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, Wang Z, Philip PA, Sarkar FH,. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
-
(2010)
Cancer Res
, vol.70
, pp. 3606-3617
-
-
Ali, S.1
Ahmad, A.2
Banerjee, S.3
Padhye, S.4
Dominiak, K.5
Schaffert, J.M.6
Wang, Z.7
Philip, P.A.8
Sarkar, F.H.9
-
80
-
-
69249096109
-
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
-
Li Y, VandenBoom TG, II, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH,. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-12.
-
(2009)
Cancer Res
, vol.69
, pp. 6704-6712
-
-
Li, Y.1
Vandenboom, I.I.T.G.2
Kong, D.3
Wang, Z.4
Ali, S.5
Philip, P.A.6
Sarkar, F.H.7
-
81
-
-
69949087531
-
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells
-
Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, Fearon ER, Lawrence TS, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009; 4: e6816.
-
(2009)
PLoS One
, vol.4
-
-
Ji, Q.1
Hao, X.2
Zhang, M.3
Tang, W.4
Yang, M.5
Li, L.6
Xiang, D.7
Desano, J.T.8
Bommer, G.T.9
Fan, D.10
Fearon, E.R.11
Lawrence, T.S.12
-
82
-
-
77953782181
-
MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand
-
Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, Abdellatif M,. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010; 285: 20281-90.
-
(2010)
J Biol Chem
, vol.285
, pp. 20281-20290
-
-
Sayed, D.1
He, M.2
Hong, C.3
Gao, S.4
Rane, S.5
Yang, Z.6
Abdellatif, M.7
-
83
-
-
69049087664
-
Cellular signaling perturbation by natural products
-
Sarkar FH, Li Y, Wang Z, Kong D,. Cellular signaling perturbation by natural products. Cell Signal 2009; 21: 1541-7.
-
(2009)
Cell Signal
, vol.21
, pp. 1541-1547
-
-
Sarkar, F.H.1
Li, Y.2
Wang, Z.3
Kong, D.4
-
84
-
-
70350225860
-
Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics
-
Sarkar FH, Li Y,. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 2009; 35: 597-607.
-
(2009)
Cancer Treat Rev
, vol.35
, pp. 597-607
-
-
Sarkar, F.H.1
Li, Y.2
-
85
-
-
33645473185
-
Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells
-
Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH,. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 2006; 5: 483-93.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 483-493
-
-
Wang, Z.1
Zhang, Y.2
Li, Y.3
Banerjee, S.4
Liao, J.5
Sarkar, F.H.6
-
86
-
-
33645064160
-
Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells
-
Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH,. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 2006; 118: 1930-6.
-
(2006)
Int J Cancer
, vol.118
, pp. 1930-1936
-
-
Wang, Z.1
Zhang, Y.2
Banerjee, S.3
Li, Y.4
Sarkar, F.H.5
-
87
-
-
78650858038
-
MiR-301a as an NF-kappaB activator in pancreatic cancer cells
-
Lu Z, Li Y, Takwi A, Li B, Zhang J, Conklin DJ, Young KH, Martin R,. miR-301a as an NF-kappaB activator in pancreatic cancer cells. EMBO J 2011; 30: 57-67.
-
(2011)
EMBO J
, vol.30
, pp. 57-67
-
-
Lu, Z.1
Li, Y.2
Takwi, A.3
Li, B.4
Zhang, J.5
Conklin, D.J.6
Young, K.H.7
Martin, R.8
-
88
-
-
68049097296
-
MicroRNAs and parallel stem cell lives
-
Dirks PB,. MicroRNAs and parallel stem cell lives. Cell 2009; 138: 423-4.
-
(2009)
Cell
, vol.138
, pp. 423-424
-
-
Dirks, P.B.1
-
89
-
-
70349142665
-
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
-
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM,. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23: 2140-51.
-
(2009)
Genes Dev
, vol.23
, pp. 2140-2151
-
-
Gibbons, D.L.1
Lin, W.2
Creighton, C.J.3
Rizvi, Z.H.4
Gregory, P.A.5
Goodall, G.J.6
Thilaganathan, N.7
Du, L.8
Zhang, Y.9
Pertsemlidis, A.10
Kurie, J.M.11
-
90
-
-
43049103824
-
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
-
DOI 10.1038/ncb1722, PII NCB1722
-
Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ,. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601. (Pubitemid 351627379)
-
(2008)
Nature Cell Biology
, vol.10
, Issue.5
, pp. 593-601
-
-
Gregory, P.A.1
Bert, A.G.2
Paterson, E.L.3
Barry, S.C.4
Tsykin, A.5
Farshid, G.6
Vadas, M.A.7
Khew-Goodall, Y.8
Goodall, G.J.9
-
91
-
-
53249130662
-
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers
-
Sabbah M, Emami S, Redeuilh G, Julien S, Prevost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C,. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008; 11: 123-51.
-
(2008)
Drug Resist Updat
, vol.11
, pp. 123-151
-
-
Sabbah, M.1
Emami, S.2
Redeuilh, G.3
Julien, S.4
Prevost, G.5
Zimber, A.6
Ouelaa, R.7
Bracke, M.8
De Wever, O.9
Gespach, C.10
-
92
-
-
68049114782
-
Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells
-
Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
-
(2009)
Cell
, vol.138
, pp. 592-603
-
-
Shimono, Y.1
Zabala, M.2
Cho, R.W.3
Lobo, N.4
Dalerba, P.5
Qian, D.6
Diehn, M.7
Liu, H.8
Panula, S.P.9
Chiao, E.10
Dirbas, F.M.11
Somlo, G.12
-
93
-
-
33847052127
-
Identification of pancreatic cancer stem cells
-
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM,. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
-
(2007)
Cancer Res
, vol.67
, pp. 1030-1037
-
-
Li, C.1
Heidt, D.G.2
Dalerba, P.3
Burant, C.F.4
Zhang, L.5
Adsay, V.6
Wicha, M.7
Clarke, M.F.8
Simeone, D.M.9
-
95
-
-
35848955428
-
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome
-
DOI 10.1016/j.stem.2007.08.014, PII S1934590907001336
-
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67. (Pubitemid 350056407)
-
(2007)
Cell Stem Cell
, vol.1
, Issue.5
, pp. 555-567
-
-
Ginestier, C.1
Hur, M.H.2
Charafe-Jauffret, E.3
Monville, F.4
Dutcher, J.5
Brown, M.6
Jacquemier, J.7
Viens, P.8
Kleer, C.G.9
Liu, S.10
Schott, A.11
Hayes, D.12
Birnbaum, D.13
Wicha, M.S.14
Dontu, G.15
-
96
-
-
33846512398
-
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma
-
DOI 10.1073/pnas.0610117104
-
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE,. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104: 973-8. (Pubitemid 46154721)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.3
, pp. 973-978
-
-
Prince, M.E.1
Sivanandan, R.2
Kaczorowski, A.3
Wolf, G.T.4
Kaplan, M.J.5
Dalerba, P.6
Weissman, I.L.7
Clarke, M.F.8
Ailles, L.E.9
-
97
-
-
1242318826
-
Sequence-specific inhibition of microRNA-and siRNA-induced RNA silencing
-
DOI 10.1261/rna.5235104
-
Meister G, Landthaler M, Dorsett Y, Tuschl T,. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004; 10: 544-50. (Pubitemid 38241013)
-
(2004)
RNA
, vol.10
, Issue.3
, pp. 544-550
-
-
Meister, G.1
Landthaler, M.2
Dorsett, Y.3
Tuschl, T.4
-
98
-
-
28444469246
-
Silencing of microRNAs in vivo with 'antagomirs'
-
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M,. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-9.
-
(2005)
Nature
, vol.438
, pp. 685-689
-
-
Krutzfeldt, J.1
Rajewsky, N.2
Braich, R.3
Rajeev, K.G.4
Tuschl, T.5
Manoharan, M.6
Stoffel, M.7
-
99
-
-
40249106014
-
Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver
-
DOI 10.1093/nar/gkm1113
-
Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjarn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36: 1153-62. (Pubitemid 351330933)
-
(2008)
Nucleic Acids Research
, vol.36
, Issue.4
, pp. 1153-1162
-
-
Elmen, J.1
Lindow, M.2
Silahtaroglu, A.3
Bak, M.4
Christensen, M.5
Lind-Thomsen, A.6
Hedtjarn, M.7
Hansen, J.B.8
Hansen, H.F.9
Straarup, E.M.10
McCullagh, K.11
Kearney, P.12
Kauppinen, S.13
-
100
-
-
42249093319
-
LNA-mediated microRNA silencing in non-human primates
-
DOI 10.1038/nature06783, PII NATURE06783
-
Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-9. (Pubitemid 351550859)
-
(2008)
Nature
, vol.452
, Issue.7189
, pp. 896-899
-
-
Elmen, J.1
Lindow, M.2
Schutz, S.3
Lawrence, M.4
Petri, A.5
Obad, S.6
Lindholm, M.7
Hedtjarn, M.8
Hansen, H.F.9
Berger, U.10
Gullans, S.11
Kearney, P.12
Sarnow, P.13
Straarup, E.M.14
Kauppinen, S.15
-
101
-
-
74249112787
-
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
-
Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H,. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
-
(2010)
Science
, vol.327
, pp. 198-201
-
-
Lanford, R.E.1
Hildebrandt-Eriksen, E.S.2
Petri, A.3
Persson, R.4
Lindow, M.5
Munk, M.E.6
Kauppinen, S.7
Orum, H.8
-
102
-
-
34548012848
-
The let-7 microRNA represses cell proliferation pathways in human cells
-
DOI 10.1158/0008-5472.CAN-07-1083
-
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22. (Pubitemid 47281364)
-
(2007)
Cancer Research
, vol.67
, Issue.16
, pp. 7713-7722
-
-
Johnson, C.D.1
Esquela-Kerscher, A.2
Stefani, G.3
Byrom, M.4
Kelnar, K.5
Ovcharenko, D.6
Wilson, M.7
Wang, X.8
Shelton, J.9
Shingara, J.10
Chin, L.11
Brown, D.12
Slack, F.J.13
-
103
-
-
77950602604
-
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma
-
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM,. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-45.
-
(2010)
Hepatology
, vol.51
, pp. 836-845
-
-
Xiong, Y.1
Fang, J.H.2
Yun, J.P.3
Yang, J.4
Zhang, Y.5
Jia, W.H.6
Zhuang, S.M.7
-
104
-
-
66449136951
-
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
-
Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT,. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-17.
-
(2009)
Cell
, vol.137
, pp. 1005-1017
-
-
Kota, J.1
Chivukula, R.R.2
O'Donnell, K.A.3
Wentzel, E.A.4
Montgomery, C.L.5
Hwang, H.W.6
Chang, T.C.7
Vivekanandan, P.8
Torbenson, M.9
Clark, K.R.10
Mendell, J.R.11
Mendell, J.T.12
-
105
-
-
77954386183
-
The road toward microRNA therapeutics
-
Seto AG,. The road toward microRNA therapeutics. Int J Biochem Cell Biol 2010; 42: 1298-305.
-
(2010)
Int J Biochem Cell Biol
, vol.42
, pp. 1298-1305
-
-
Seto, A.G.1
-
106
-
-
60849101337
-
MicroRNAs: Key players in carcinogenesis and novel therapeutic targets
-
Mirnezami AH, Pickard K, Zhang L, Primrose JN, Packham G,. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol 2009; 35: 339-47.
-
(2009)
Eur J Surg Oncol
, vol.35
, pp. 339-347
-
-
Mirnezami, A.H.1
Pickard, K.2
Zhang, L.3
Primrose, J.N.4
Packham, G.5
-
107
-
-
77957361864
-
Targeting microRNAs in cancer: Rationale, strategies and challenges
-
Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 775-789
-
-
Garzon, R.1
Marcucci, G.2
Croce, C.M.3
-
108
-
-
77953022034
-
Implication of microRNAs in drug resistance for designing novel cancer therapy
-
Sarkar FH, Li Y, Wang Z, Kong D, Ali S,. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 2010; 13: 57-66.
-
(2010)
Drug Resist Updat
, vol.13
, pp. 57-66
-
-
Sarkar, F.H.1
Li, Y.2
Wang, Z.3
Kong, D.4
Ali, S.5
|